New drug combo aims to control advanced cervical cancer with fewer side effects
NCT ID NCT07143292
First seen Nov 18, 2025 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests three different doses of famitinib malate combined with camrelizumab in 120 people with recurrent or metastatic cervical cancer that cannot be cured by standard treatments. The goal is to find the dose that best controls the cancer while reducing serious side effects. Participants will take the drugs daily and be monitored for tumor response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.